G2163 — Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period
G2163 is a HCPCS Level II code for patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period. It belongs to the Procedures and Professional Services (Temporary) section. It was terminated on December 31, 2020 and is not valid on new claims.
This code has been terminated
CMS terminated G2163 on December 31, 2020. It stays in the file as history — a claim you are auditing from before that date may legitimately carry it — but it must not appear on a new claim. The adjacent codes below are the usual place to look for its replacement.
Medicare coverage: Carrier judgment
Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.
The CMS record for G2163
- Long descriptor
- Patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period
- Short descriptor
- Infl vacc 07/01 to 06/30
- Added
- January 1, 2020
- Terminated
- December 31, 2020
- BETOS
- Z2
- Pricing indicator
- 00 — Not priced by Part B
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
When CMS retired it.
Berenson-Eggers Type of Service — CMS's own analytic grouping.
Service not separately priced by Part B — not covered, bundled into another service, or used by Part A only.
Codes adjacent to G2163
HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If G2163 is not quite right, the correct code is very often within a few positions of it.
- G2155Patient had history of at least one of the following contraindications any time during or before the measurement period: anaphylaxis due to tdap vaccine, anaphylaxis due to td vaccine or its components; encephalopathy due to tdap or td vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis or post pertussis vaccination encephalitis.)terminated
- G2156Patient did not receive at least one td vaccine or one tdap vaccine between nine years prior to the start of the measurement period and the end of the measurement period; or have history of at least one of the following contraindications any time during or before the measurement period: anaphylaxis due to tdap vaccine, anaphylaxis due to td vaccine or its components; encephalopathy due to tdap or td vaccination (post tetanus vaccination encephalitis, post diphtheria vaccination encephalitis or post pertussis vaccination encephalitis.)terminated
- G2157Patients received both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during the measurement periodterminated
- G2158Patient had prior pneumococcal vaccine adverse reaction any time during or before the measurement periodterminated
- G2159Patient did not receive both the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine at least 12 months apart, with the first occurrence after the age of 60 before or during measurement period; or have prior pneumococcal vaccine adverse reaction any time during or before the measurement periodterminated
- G2160Patient received at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement periodterminated
- G2161Patient had prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement periodterminated
- G2162Patient did not receive at least one dose of the herpes zoster live vaccine or two doses of the herpes zoster recombinant vaccine (at least 28 days apart) anytime on or after the patient's 50th birthday before or during the measurement period; or have prior adverse reaction caused by zoster vaccine or its components any time during or before the measurement periodterminated
- G2164Patient had a prior influenza virus vaccine adverse reaction any time before or during the measurement periodterminated
- G2165Patient did not receive an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period; or did not have a prior influenza virus vaccine adverse reaction any time before or during the measurement periodterminated
- G2166Patient refused to participate at admission and/or discharge; patient unable to complete the neck fs prom at admission or discharge due to cognitive deficit, visual deficit, motor deficit, language barrier, or low reading level, and a suitable proxy/recorder is not available; patient self-discharged early; medical reasonterminated
- G2167Residual score for the neck impairment successfully calculated and the score was less than zero (< 0)
- G2168Services performed by a physical therapist assistant in the home health setting in the delivery of a safe and effective physical therapy maintenance program, each 15 minutes
- G2169Services performed by an occupational therapist assistant in the home health setting in the delivery of a safe and effective occupational therapy maintenance program, each 15 minutes
- G2170Percutaneous arteriovenous fistula creation (avf), direct, any site, by tissue approximation using thermal resistance energy, and secondary procedures to redirect blood flow (e.g., transluminal balloon angioplasty, coil embolization) when performed, and includes all imaging and radiologic guidance, supervision and interpretation, when performedterminated
- G2171Percutaneous arteriovenous fistula creation (avf), direct, any site, using magnetic-guided arterial and venous catheters and radiofrequency energy, including flow-directing procedures (e.g., vascular coil embolization with radiologic supervision and interpretation, wen performed) and fistulogram(s), angiography, enography, and/or ultrasound, with radiologic supervision and interpretation, when performedterminated
Questions about G2163
What is HCPCS code G2163?
G2163 is a HCPCS Level II code for patient received an influenza vaccine on or between july 1 of the year prior to the measurement period and june 30 of the measurement period. It sits in the Procedures and Professional Services (Temporary) section.
Does Medicare cover G2163?
The CMS HCPCS file marks G2163 as "Carrier judgment". Coverage is decided by your Medicare contractor, not by national policy. Whether this is paid depends on the LCD for your jurisdiction and on what the documentation supports.
Is G2163 still valid?
No. G2163 was terminated on December 31, 2020 and should not be used on new claims.